Aditxt Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
virginir.com/10228263

RICHMOND, Va. ~ Aditxt, Inc. (NASDAQ: ADTX), an innovation company focused on monitoring and modulating the immune system, has entered into definitive agreements for the purchase and sale of 1,000,000 shares of common stock (or pre-funded warrant in lieu thereof) at a purchase price of $10.00 per share (or pre-funded warrant in lieu thereof) and accompanying warrants to purchase one share of common stock at an exercise price of $10.00 per share. The private placement is expected to close on or about September 5, 2023, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering with gross proceeds from the offering expected to be $10 million prior to deducting placement agent's fees and other offering expenses payable by Aditxt. The company intends to use the net proceeds from the offering for working capital and other general corporate purposes.

More on virginir.com

• Dogs at the Dentist: How an unlikely partnership is helping treat dental anxiety
• E*TRADE from Morgan Stanley Releases Monthly Sector Rotation Study
• SSV Network selects Randamu for Distributed Key Generation (DKG) Grant Award
• Exceptional US Navy Wood Military Signs
• Lawmato relaunches its virtual consultation app with enhanced features

The securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and/or Regulation D promulgated thereunder and have not been registered under the Securities Act or applicable state securities laws. Accordingly, they may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

Aditxt is a global innovation company that develops therapeutics and technologies with a focus on monitoring and modulating the immune system. Its mission is "Making Promising Innovations Possible, Together" which is defined by its growing ecosystem of research institutions, global industry partners and shareholders who inform and inspire its mission. Aditxt's diverse innovation portfolio includes Adimune, Inc., Adivir, Inc., and Pearsanta, Inc., which are focused on developing new ways to treat organ rejection, autoimmunity, allergies, infectious diseases as well as personalized immune monitoring intended for a wide range of health conditions including hereditary cancer wounds and cardiomyopathy respectively.

---

Show All News | Report Violation